Altered microbiome composition in individuals with fibromyalgiaOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether gut microbiome composition differs in people with fibromyalgia (FM), a syndrome marked by chronic widespread pain, fatigue, and impaired sleep. Researchers compared microbiome profiles using both 16S rRNA gene amplification and whole-genome sequencing. They also measured serum levels of the short-chain fatty acids butyrate and propionate to see whether metabolite changes tracked with any bacterial shifts. The design combined differential abundance analysis, variance analysis against clinical and environmental variables, and machine-learning classification.
Who was studied?
The study population consisted of 77 women diagnosed with fibromyalgia and 79 control participants who were unrelated to the patients. Microbiome data came from stool samples analyzed by 16S rRNA sequencing and whole-genome sequencing, paired with targeted serum metabolite testing in the same participants. No further demographic or geographic details were given in the abstract.
What were the most important findings?
Differential abundance analysis revealed significant differences in several bacterial taxa between FM patients and controls. Variance in microbiome composition was explained by FM-related variables more than by any other innate or environmental factor, and this variance correlated with clinical indices of FM. Consistent with alterations in butyrate-metabolizing bacterial species, serum levels of butyrate and propionate also differed in FM patients. Using machine-learning algorithms, microbiome composition alone classified patients versus controls with a receiver operating characteristic area under the curve of 87.8%.
What are the greatest implications of this study?
This is described as the first demonstration of gut microbiome alteration in a nonvisceral pain condition, extending microbiome-disease links beyond gut-localized disorders. The strong classification performance suggests the microbiome could potentially serve as a diagnostic aid for fibromyalgia, a syndrome that is otherwise difficult to diagnose. The link to altered butyrate and propionate levels points toward specific metabolic pathways that may warrant further mechanistic study. The authors frame these findings as a foundation for future work on FM pathophysiology and possible new treatment approaches.